Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Bařinová M, Kuhn M, Šilar J, Čápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Hájek R, et al. Among authors: brozova l. Future Oncol. 2021 Jul;17(19):2499-2512. doi: 10.2217/fon-2020-1225. Epub 2021 Mar 26. Future Oncol. 2021. PMID: 33769076 Free article.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Capkova L, Sykora M, Kessler P, Stejskal L, Heindorfer A, Ullrychova J, Skacel T, Maisnar V, Hajek R. Minarik J, et al. Among authors: brozova l. BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1. BMC Cancer. 2021. PMID: 33451293 Free PMC article.
Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, Radocha J, Gregora E, Stecova N, Jelinek T, Jungova A, Kralikova E, Brozova L, Hajek R. Maisnar V, et al. Among authors: brozova l. Neoplasma. 2019 May 23;66(3):499-505. doi: 10.4149/neo_2018_180824N644. Epub 2019 Feb 14. Neoplasma. 2019. PMID: 30784289
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R. Radocha J, et al. Among authors: brozova l. Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21. Cancer Med. 2018. PMID: 29931775 Free PMC article.
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R. Minarik J, et al. Among authors: brozova l. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019. PMID: 30397362 Free article.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, Minařík J, Pavlíček P, Radocha J, Heindorfer A, Jelínek T, Stejskal L, Brožová L, Ševčíková S, Straub J, Pika T, Pour L, Maisnar V, Seckinger A, Hose D. Hájek R, et al. Among authors: brozova l. Br J Haematol. 2020 Jul;190(2):189-197. doi: 10.1111/bjh.16572. Epub 2020 Mar 12. Br J Haematol. 2020. PMID: 32163180 Free article.
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Sandecká V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Heindorfer A, Pavlíček P, Sýkora M, Jungová A, Kessler P, Wróbel M, Starostka D, Ullrychová J, Stejskal L, Štork M, Straub J, Pika T, Brožová L, Ševčíková S, Maisnar V, Hájek R. Sandecká V, et al. Among authors: brozova l. Eur J Haematol. 2021 Oct;107(4):466-474. doi: 10.1111/ejh.13683. Epub 2021 Jul 28. Eur J Haematol. 2021. PMID: 34272773
Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, Brozova L, Jarkovsky J, Spicka I, Straub J, Pavlicek P, Jungova A, Jelinek T, Sandecka V, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: brozova l. Br J Haematol. 2022 Feb;196(4):954-962. doi: 10.1111/bjh.17925. Epub 2021 Nov 2. Br J Haematol. 2022. PMID: 34726261 Free PMC article.
42 results